Your Messages Inbox
Your Article Summary
See Latest Articles
Shire plc, the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application for DAYTRANA for the treatment of Attention Deficit Hyperactivity Disorder. A request from European regulators to conduct an additional clinical study on DAYTRANA in a European patient population combined with the recently announced planned acquisition of the worldwide rights to EQUASYM IR and XL for the treatment of ADHD are the basis for this decision.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
Bristol Myers-Squibb Company, 12/07/09
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Article Search
Sponsor